Symposium 11: ‘New Drug Modalities for the Treatment of Hemostatic and Thrombotic Disorders’
Title: ‘Development of novel aptamer blocking the interaction between VWF A1 domain and platelet GP Ib for the treatment of arterial thrombosis’
Exploring the potential of the novel IFNγ aptamer TAGX-0003 as a treatment for alopecia areata in pre-clinical models
Markus Fehrholz1*, Kaori Harada2*, Ilaria Piccini1, Amos Gilhar3, Susumu Muto2**, Marta Bertolini1**
*and**Both authors contributed equally as first authors and corresponding authors to this work, respectively.
1Monasterium Laboratory, Münster, Germany
2TAGCyx Biotechnologies Inc, Tokyo, Japan
3Technion-Israel Institute of Technology, Haifa, Israel
2021 European Society for Dermatological Research (ESDR) Annual Meeting (virtual)
Results of joint research with Prof. Taiichi Sakamoto, Chiba Institute Technology on the recognition mechanism of Xenoligo® against target proteins based on the structural analysis will be presented in a poster at 22nd International Society of Magnetic Resonance Conference, the 9th Asia-Pacific NMR Symposium, the 60th Annual Meeting of the Nuclear Magnetic Resonance Society of Japan (2021), and the 60th Annual Meeting of the Society of Electron Spin Science and Technology (online), which will be held on the 22nd to 27th of August.
August 24, 2021, 8:40〜10:40
Session of Solution NMR: Biological Applications
Poster number: P1-2-16
NMR Analysis of Interaction between an ssDNA Aptamer Containing Artificial Base Ds and VEGF165
○Tomomi Nagahama, Tatsuhiko Someya, Susumu Muto, Taiichi Sakamoto
Details is obtained here;
Our pipeline is updated.
TAGCyx Biotechnologies, Inc. (Tokyo, Japan) has raised approximately 210 million JPY from UTokyo Innovation Platform Co., Ltd., SBI Group and Healthcare Innovation Co., Ltd.
TAGCyx is developing unique DNA aptamers called “Xenoligo®” for therapeutic purpose, using proprietary artificial nucleic acid base pair technology. Oligonucleotide aptamers are single strand DNA or RNA that bind to specific molecules due to its unique 3-D structure. Xenoligo® has features of high binding affinity to proteins by particular hydrophobic interaction of proprietary artificial bases and stabilization by proprietary Mini-hair pin technology, therefore it is possible to generate and develop Xenoligo® for therapeutic purpose.
Based on the platform technology of Xenoligo®, TAGCyx has concentrated management resources in the drug discovery business since 2016, and through multiple steps of financing, has entered into several collaboration agreements with pharmaceutical and healthcare companies. Achieving this funding, TAGCyx will accelerate the expansion and stage-up of development pipeline and contribute to healthcare.